Is Anika Therapeutics, Inc. (ANIK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 12.9% / 30% | 28.2% / 30% | 11.6% / 30% | 0.0% / 5% | ✓ HALAL |
| DJIM | 12.9% / 33% | 28.2% / 33% | 11.6% / 33% | 0.0% / 5% | ✓ HALAL |
| MSCI | 13.8% / 33% | 30.2% / 33% | 12.5% / 33% | 0.0% / 5% | ✓ HALAL |
| S&P | 12.9% / 33% | 28.2% / 33% | 11.6% / 33% | 0.0% / 5% | ✓ HALAL |
| FTSE | 13.8% / 33% | 30.2% / 33% | 12.5% / 50% | 0.0% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 56.6% | |
| Operating Margin | 2.1% | |
| Net Margin | -9.6% | |
| Return on Equity (ROE) | -6.7% | |
| Return on Assets (ROA) | -3.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $11M |
| Free Cash Flow | $4M |
| Total Debt | $26M |
| Debt-to-Equity | 18.3 |
| Current Ratio | 4.7 |
| Total Assets | $190M |
Price & Trading
| Last Close | $14.75 |
| 50-Day MA | $11.87 |
| 200-Day MA | $10.23 |
| Avg Volume | 146K |
| Beta | 0.3 |
|
52-Week Range
$7.87
| |
About Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Anika Therapeutics, Inc. (ANIK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Anika Therapeutics, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Anika Therapeutics, Inc.'s debt ratio?
Anika Therapeutics, Inc.'s debt ratio is 12.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.8%.
What are Anika Therapeutics, Inc.'s key financial metrics?
Anika Therapeutics, Inc. has a market capitalization of $206M, and revenue of $113M. The company maintains a gross margin of 56.6% and a net margin of -9.6%. Return on equity stands at -6.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.